The global ADME Toxicology Testing Market is expanding as pharmaceutical and biotechnology companies increasingly focus on improving drug safety and reducing late-stage development failures. ADME toxicology testing evaluates absorption, distribution, metabolism, excretion, and toxicity characteristics during preclinical drug development. Growing biologics research, precision medicine, advanced in-vitro testing, high-throughput screening, artificial intelligence, and predictive toxicology technologies are supporting market growth. Increasing outsourcing of preclinical studies to contract research organizations (CROs) is also strengthening demand for specialized testing services.

According to Fortune Business Insights, the global ADME toxicology testing market was valued at USD 7.12 billion in 2025 and is projected to grow from USD 7.84 billion in 2026 to USD 17.00 billion by 2034, exhibiting a CAGR of 10.15% during the forecast period.

Why is the ADME Toxicology Testing Market Growing?

The growing volume of pharmaceutical and biologics research is a major factor driving the market. Drug developers increasingly use ADME and toxicology studies to evaluate drug metabolism, pharmacokinetic behavior, toxicity risks, and potential drug interactions before clinical development.

ADME toxicology testing is increasingly used for:

• Pharmaceutical drug development
• Biologics development
• Cell and gene therapies
• Monoclonal antibodies
• Oncology research
• Rare disease research
• Precision medicine
• Drug metabolism studies
• Toxicity screening
• Pharmacokinetic evaluation

The increasing use of CROs is also helping pharmaceutical companies access specialized laboratory infrastructure, advanced analytical technologies, and experienced toxicology professionals without maintaining all capabilities internally.

Key Market Trends Shaping Industry Growth

Increasing Adoption of In-Vitro Testing

One of the most important trends is the shift toward in-vitro toxicology testing, which can reduce reliance on animal-based experimentation while providing controlled environments for evaluating toxicity, metabolism, and cellular responses.

In-vitro methods account for approximately 47% of the market. Microfluidic systems, organ-on-chip technologies, human-derived cell models, and automated cellular-analysis platforms are increasingly being incorporated into modern toxicology workflows.